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ABSTRACT
Objectives: The objective of this proof of concept
study was to evaluate alerts generated by a patient-
reported outcome measure (PROM)-based algorithm
for monitoring patients with rheumatoid arthritis (RA).
Methods: The algorithm was constructed using an
example PROM score of an equally weighted mean of
visual analogue scale (VAS) general health, VAS
disease activity and VAS pain. Based on the PROM
score, red flags are generated in 2 instances: the target
level of disease activity is not met; change in disease
activity surpasses an early alert threshold. To reduce
false alarms, 3 consecutive red flags are needed to
trigger an alert to the physician. Time series data from
patients included consecutively in the practice-based
Nijmegen Early RA cohort were analysed to select an
appropriate autoregressive integrated moving average
(ARIMA) model. This allowed for advanced
interpolation of PROM scores and weekly data
evaluation. Alerts were evaluated against disease-
modifying antirheumatic drug (DMARD)/biologic
medication intensification registered in the cohort.
Results: Data of 165 patients followed in their second
year postdiagnosis were analysed. In 89.8% of 716
visits, the algorithm did not generate an alert and
medication was not escalated. Positive predictive value,
sensitivity and specificity were 24.6%, 55.6% and
69.7%, respectively. Comparable performance was
found when analyses were stratified for baseline
Disease Activity Score 28-joint count (DAS28) level.
Conclusions: When using the algorithm to screen
scheduled visits, the overall chance of missing patients
in need of medication intensification is low. These
findings provide evidence that an off-site monitoring
system could aid in optimising the number and timing
of face-to-face consultations of patients with their
rheumatologists.
INTRODUCTION
Several patient-reported outcome measure
(PROM)-based instruments exist to assess
disease activity in rheumatoid arthritis
(RA).1–7 To date, these instruments have pre-
dominantly been used for research purposes,
though an evidence base for their use in
monitoring strategies in daily practice is
lacking. This is unfortunate, for PROM-based
instruments offer the unique potential to get
patients more involved in their disease man-
agement, while producing valuable data on
the disease course from the patient’s per-
spective. A secondary beneﬁt is that PROM-
based instruments are location-independent
and time-independent, offering the possibil-
ity for ﬂexible, patient-tailored off-site moni-
toring and management. A possible
explanation why PROMs are not often uti-
lised could be related to reports that show
differing disease perceptions between
patients and physicians.8–10 This means that
Key messages
What is already known about this subject?
Treat-to-target strategies have been shown to be
effective in treating rheumatoid arthritis (RA). Most
of these strategies are based on physician-reported
measures, even though several patient-reported
outcome measure (PROM)-based instruments to
assess disease activity in RA exist.
What does this study add?
This study is a first proof of concept that a
PROM-based algorithm can aid physicians in
screening patients’ disease activity prior to sched-
uled outpatient visits taking place.
How might this impact on clinical practice?
An off-site monitoring system based on PROMs
could aid in optimising the number and timing of
face-to-face consultations of patients with their
rheumatologists. Furthermore, this could help
empower patients to manage their disease and
make informed shared decisions with their
physicians.
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the translation of PROM-based scores, and the changes
thereof, into treatment targets and monitoring guide-
lines is far from straightforward. The question that arises
is how patient-reported data on disease activity in RA
should be interpreted and how well this corresponds to
clinical medication decisions. The objective of this study
was to evaluate alerts generated by a PROM-based algo-
rithm for monitoring patients with RA.
METHODS
Study design and setting
This study was a simulation study based on retrospective
cohort data. Data from patients with a complete second-
year follow-up after diagnosis, included consecutively in
the Nijmegen early RA cohort between 2003 and 2011,
were used. This study population was chosen as a proof
of concept. It represents patients beyond the initial
intensive phase of treatment, though where disease activ-
ity might still ﬂuctuate, indicating the need for adequate
monitoring.
PROM-based algorithm
On the basis of discussions with experts in the ﬁeld of
rheumatology (see Acknowledgements section) and
meetings with patient partners attending Disease Activity
Score 28-joint count (DAS28) training sessions at the
Radboud University Medical Center, the idea of an
off-site monitoring strategy based on PROM scores was
formulated. As an example of a PROM score of RA
disease activity, an equally weighted mean of: visual ana-
logue scale (VAS) general health, VAS disease activity
and VAS pain, was used. These component scores were
chosen as they are often collected as core set measures
and would be likely to be responsive to weekly variations
in disease activity. Monitoring of the score is focused on
two components:
1. The target level of disease activity;
2. Change in disease activity (current level vs best
moving average of 3 past visits).
To allow for empowerment of patients in the monitor-
ing of their disease, preliminary targets (which can be
optionally tailored to the individual patient) are based
on clinimetric measures, which include the patient per-
spective. Patient acceptable symptom state (PASS) is used
for the upper level of disease activity. To prevent favour-
able scores gradually returning to higher levels, an early
alert threshold for change in disease activity is based on a
minimal important change (MIC) value. Default values
for PASS and MIC are derived from an OMERACT con-
sensus meeting and are set at 40 mm and 20 mm, respect-
ively.11 A downside to MIC or PASS cut-off values is that
misclassiﬁcation could arise when monitoring is based
only on either MIC or PASS.12–15 For example, a patient
might have a positive perception of the achieved disease
course trajectory (MIC), however, he or she might not
have achieved the desired health state (PASS). When
solely focusing on either MIC or PASS, this can lead to
misinterpretation of the PROM score and the views of
the respective patient. Therefore, the algorithm monitors
the PROM score on MIC and PASS targets, and if either
one is not met, red ﬂags are generated (ﬁgure 1).
To allow for timely detection of high disease activity in
need of consultation, a weekly measurement frequency
was proposed. PROM-based scores can, however, ﬂuctu-
ate considerably from week to week.16 To reduce the
chance of many false alarms, three consecutive red ﬂags
are needed to trigger an alert to the physician, indicat-
ing the need for further consultation (ﬁgure 1). After
three red ﬂags and an alert is generated, the three-span
best moving average resets and the algorithm recali-
brates over a 4-week period, to allow for any therapy
alterations to take effect before new red ﬂags are
generated.
Generation of weekly data based on existing data
As mostly only monthly and three monthly data were
available in our registry, weekly data needed for the
evaluation of the algorithm had to be simulated. This
Figure 1 Preliminary
PROM-based algorithm (MIC,
minimal important change; PASS,
patient acceptable symptom state;
PROM, patient-reported outcome
measure; VAS, visual analogue
scale).
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was carried out by an advanced form of interpolation.
First, ﬂuctuations of PROM scores of 29 patients
who were stable on synthetic disease-modifying antirheu-
matic drugs (sDMARD) and/or biologic DMARDs
(bDMARD), with at least 10 assessments, were inspected
using time series analysis to select an appropriate fore-
casting model. These patients were not included in the
algorithm evaluation. Based on the time series analysis,
an autoregressive integrated moving average (ARIMA
1,0,0) with heterogeneous variances and random inter-
cept was ﬁtted to the data.17 A correlation of 0.5
between monthly scores was found, with a SD between
11 and 13.5 around the mean PROM score at each time
point characterising residual variance. Next, weekly data
were simulated by ﬁrst interpolating weekly data
between registered data minus random error based on
the residual variance seen in stable patients and then
adding random error to the interpolated scores.
Supplementary information on the ARIMA model selec-
tion and data simulation can be found in online
supplementary appendix I.
Statistical evaluation of the algorithm
Alerts were evaluated against sDMARD or bDMARD
medication intensiﬁcation within 1 month of the out-
patient visit, as an external standard. Intensiﬁcation was
deﬁned as an increase in dose/frequency or start of new
drug. Performance of the algorithm was analysed by
cross-tabulating alerts generated by the algorithm
against the external standard, and inspecting positive
predictive values (PPVs) and negative predictive values
(NPVs). Analyses were also stratiﬁed according to DAS28
level at 12 months. All analyses were performed using
IBM SPSS Statistics V.20.0.0.2.
RESULTS
Data of 165 patients with RA visiting the outpatient
clinic 716 times were available for analysis; most patients
(90.3%) had between 4 and 6 visits in the 12 months of
follow-up in the second year postdiagnosis. These
patients represent a sample of a population that is seen
in daily clinical practice (table 1). Most patients were
female, rheumatoid factor positive and had short disease
duration at the time of diagnosis. Disease activity was low
(DAS28<3.2) for 55% of the patients, and most patients
used methotrexate. Of the 716 visits, a total of 108 medi-
cation intensiﬁcations took place within 1 month of the
visit: 31 dose increases and 77 starts of new medications.
Consequently, the a priori chance of medication intensi-
ﬁcations was 15.1%.
The association of DAS28 categories with the example
PROM score is illustrated in ﬁgure 2. Validity of the
PROM score and the 40 point threshold used in the
algorithm is substantiated as most patients below the
threshold are categorised in low or remission DAS28 cat-
egories. Figure 3 shows an example of how these simu-
lated PROM scores result in ﬂuctuations that more
closely resemble ﬂuctuations seen in practice than those
based on standard linear interpolation of registered
PROM scores.
An overview of the algorithm performance is shown in
table 2. The NPVs represent the proportion of visits
without medication intensiﬁcation in all cases where the
algorithm indeed did not generate an alert, which was
424/472 (89.8%). In 18/48 (37.5%) of the cases where
there was a false-negative result, this was due to intensiﬁ-
cation of the current drug and 11/18 (61.1%) of these
intensiﬁcations were small increases in methotrexate
doses (2.5–5 mg). The PPVs represent the proportion of
visits with medication intensiﬁcation in all cases where
the algorithm also generated an alert. This was the case
in 24.6% of all visits, which is an improvement over the
a priori chance of 15.1%.
The performance, stratiﬁed according to DAS28 level
at baseline (12 months postdiagnosis in this analysis),
showed very similar results when compared with overall
performance (table 2). As is to be expected, the a priori
chance of medication intensiﬁcation and PPVs increase
with higher DAS28 levels.
DISCUSSION
The objective of this study was to evaluate alerts gener-
ated by a PROM-based algorithm for monitoring
patients with RA, against intensiﬁcations of antirheu-
matic medications. The PPVs, though low, were an
improvement over the a priori chance of medication
intensiﬁcation. In case an alert is raised, the overall
chance of medication intensiﬁcation was 24.6% instead
of 15.1%. The NPV of 89.8% indicates that the algo-
rithm performed very well at indicating which patients
were not in need of medication intensiﬁcation, and this
was an improvement over the a priori chance of 84.9%
not intensifying medication. In total, this means that
knowing the result of the algorithm improves the a
priori knowledge by 14.4% (9.5%+4.9%). If the
Table 1 Patient characteristics at first visit during
second-year follow-up postdiagnosis
Number of patients 165
Age 57.3 (13.7)*
Female 59%
Rheumatoid factor positive 60%
Disease duration in months 12.5 (11.8–13.2)†
DAS28 3.0 (1.1)*
PROM score 32 (24)*
Receiving DMARD 78% (Methotrexate)‡
Receiving biologic 13% (Adalimumab)‡
*Mean (SD).
†Median (IQR).
‡Most prevalent agent.
DAS28, Disease Activity Score 28-joint count; DMARD,
disease-modifying antirheumatic drug; PROM score,
patient-reported outcome measure score consisting of an equally
weighted mean of visual analogue scales for general health, pain
and disease activity.
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algorithm is used in daily practice to screen scheduled
visits, this could mean a possible reduction of visits, with
a relatively small overall chance of missing patients in
need of medication intensiﬁcation. The sensitivity and
speciﬁcity values were 55.6% and 69.7%, respectively.
Although these values might seem low from a diagnostic
perspective, they are quite promising for a low cost, low
effort screening tool. One must also not forget that, due
to a low prevalence of medication intensiﬁcation, the
absolute number of visits with medication intensiﬁcation
missed by the algorithm is small (48), and relative to the
total number of visits (716), this amounts to a low
overall chance of missing these patients (48/716=6.7%).
Moreover, the value of using PROMs for monitoring
extends beyond improving diagnostic performance of
ﬁxed monitoring strategies. By actively engaging patients
in relating their symptoms to a disease activity score
(DAS), they are better informed on the concept of
disease activity. Patients can then become more empow-
ered to make informed shared decisions with their physi-
cians. Vice versa, rheumatologists become more
informed about their patients’ experiences of their
disease in between visits. A patient’s experience might
not always correlate with clinical measures of disease
activity, as PROMs can be inﬂuenced by irreversible
damage. However, knowing how patients perceive their
disease is valuable, as this will form the basis on which
patients will judge their disease course and make deci-
sions with regard to treatment.
The ﬁndings of this study provide a ﬁrst proof of
concept that an off-site monitoring system could aid in
optimising the number and timing of face-to-face
Figure 2 Boxplots of
patient-reported outcome
measure (PROM) scores by
Disease Activity Score 28-joint
count (DAS28) categories.
Table 2 PROM-based algorithm performance
Visits PPV NPV Sensitivity Specificity
A priori chance
of intensification
Total 716 24.6 89.8 55.6 69.7 15.1
Stratified according to DAS2812 months*
DAS28<2.6 287 16.1 93.8 41.7 80.2 8.0
DAS28 ≤3.2 and ≥2.6 105 33.3 92.0 62.5 77.5 15.2
DAS28 <5.1 and >3.2 287 25.8 83.2 52.5 61.0 20.6
DAS28≥5.1 35 28.1 100 100 11.5 25.7
*For two visits, the baseline DAS28 value was not available, neither of the visits generated an alert and medication was not intensified.
DAS28, Disease Activity Score 28-joint count; NPV, negative predictive value; PPV, positive predictive value; PROM, patient-reported outcome
measure.
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consultations of patients with their rheumatologists. An
alternative analysis where a single red ﬂag would trigger
an alert resulted in a lower PPV (22.4%), due to a higher
false-positive percentage. The monitoring performance
of the proposed algorithm might be further enhanced if
it is tailored to the patient as time passes and more infor-
mation about each patient is collected. Based on individ-
ual patient characteristics, for example, Anti–citrullinated
protein antibody (ACPA) status, the patients’ individual
goals and/or sensitivity to detect changes in their disease
course, the number of red ﬂags needed to trigger an
alert, the target level and/or early alert threshold could
be adjusted to best suit the patient.18
As this study is a ﬁrst proof of concept, it is not
without limitations. First, we chose to demonstrate the
algorithm with an example PROM score based on VAS
general health, VAS disease activity and VAS pain. Some
studies have reported interchangeability of VAS general
health and VAS disease activity for calculation of the
DAS28.
19 20 This does not automatically mean that they
measure the same health aspect, because the VAS scores
are heavily down-weighted in the DAS formulae and cor-
relations between the actual VAS scores are often only
moderate.19–21 In our study population, the correlations
between the three component VAS scores ranged,
respectively, between 0.81, 0.82 and 0.86, and differed
more than 10 points for approximately 25% of individ-
ual patients. A second limitation, due to the retrospect-
ive study design, was the lack of weekly data to evaluate
the algorithm. To overcome this, we used an advanced
form of interpolation based on time series analysis to
make the best use of existing data. The resulting individ-
ual patient data (sample of 5 patients shown in ﬁgure 3)
showed weekly ﬂuctuations following long-term linear
trends. These patterns correspond quite well to those
that have been reported by Blanchais et al,16 who have
presented data of 26 patients who were followed on a
weekly basis. Similar to their study, where Routine
Assessment of Patient Index Data 3 (RAPID3) scores
within patients varied up to 3 points (out of 10) from
1 week to the next, our weekly generated PROM scores
varied up to 24 points (out of 100). A third limitation of
this study was that it only focused on medication intensi-
ﬁcation as an outcome to measure performance. There
are, of course, other reasons, such as adverse drug
effects, that would call for consultation with a physician.
This brings to light an important consideration when
trying to use monitoring algorithms; these cannot, and
should never, completely replace common sense or clin-
ical reasoning. In cases such as adverse drug effects,
patients should contact their physician in the same
manner as they would do in standard daily practice.
Further investigation into the optimal PROM score,
measurement frequency and algorithm parameter values
to be used for off-site monitoring seems warranted,
given the many potential beneﬁts and the positive
results of this proof of concept study. The value of a
PROM-based algorithm lies in systematically collecting
individual patient data, utilising it with the best knowl-
edge for current practice and further inspecting it to
optimise future practice. Making more use of PROMs
for monitoring in daily practice could lead to effective
Figure 3 Results of advanced interpolation based on time series analysis versus standard linear interpolation for five randomly
drawn patients (PROM, patient-reported outcome measure).
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and efﬁcient strategies, in which care is centred on the
patient, who is empowered to manage the disease and
make informed, shared decisions with their physicians.
Twitter Follow Jos Hendrikx at @joshendrikx
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